TREATMENT OF ANCA-ASSOCIATED VASCULITIS AN UPDATE. Loïc Guillevin. Hôpital Cochin, Université Paris Descartes. DU MALADIES SYSTEMIQUES, 7 March 2014
|
|
- Chester Glenn
- 5 years ago
- Views:
Transcription
1 TREATMENT OF ANCA-ASSOCIATED VASCULITIS AN UPDATE Loïc Guillevin Hôpital Cochin, Université Paris Descartes DU MALADIES SYSTEMIQUES, 7 March
2 Disclosure of interest regarding this presentation Former member of the Scientific Council of the Rituximab Registry for Autoimmune Diseases in France Roche has provided, in part, rituximab for the MAINRITSAN 1 and 2 clinical trials 2
3 CONVENTIONAL TREATMENT FOR VASCULITIS Cyclophosphamide + steroids in systemic disease Methotrexate for non-renal GPA CS alone in some patients without poorprognosis factors (FFS 0) (EGPA, MPA) Azathioprine or methotrexate for maintenance treatment 3
4 HOW TO TREAT VASCULITIDES Pulse cyclophosphamide treatment 0.6 to 0.7gr/sq.m (or 15 mg/kg) D0, D15, D30 then every 3 weeks until remission 0.5 gr/sq.m in case of renal insufficiency or in patients > 65 yr.old 4
5 CLINICIAN S AND PATIENT S NEEDS Quick effectiveness Good tolerance Cure more thanobtaina remission 5
6 6
7 Rapid crescentic glomerulonephritis 7
8 Fibrine Capsular rupture Extracapillary proliferation 8
9 QUICK EFFECTIVENESS: PLASMA EXCHANGES 9
10 SeverePAN withouthbv, CSS and MPA Indication of plasma exchanges CS+IV CYC vs CS +IV CYC +PE Guillevin, Arthritis Rheum 1995; 38: 1683 Guillevin, Arthritis Rheum 1995; 38:
11 Guillevin, Arthritis Rheum 1995; 38:
12 PLASMA EXCHANGES IN SEVERE AAV Plasma exchanges MEPEX Comparisonof pulses MPS to PE in ANCA+ vasculitiswith creatininemia> 500 µmol/l 150 patients Jayne D et al, JASN
13 PLASMA EXCHANGES IN SEVERE AAV Patient survival Group IV MeP.2.1 Pl Ex Survival Months from entry Jayne, JASN 2007, 18:
14 PLASMA EXCHANGES IN SEVERE AAV Renal recovery.6.4 Group.2 IVMep P Ex Renal recovery Months from entry Jayne, JASN 2007, 18:
15 PEXIVAS Randomised trial of plasma exchange and glucocorticoids in ANCA associated vasculitis 15
16 Hypothesis 1. PLEX increases the time to develop ESRD or death in severe AAV 2. Reduced GC will not increase ESRD or death and will reduce adverse events (esp. infections) 16
17 Eligibility ANCA vasculitis (new or relapsing) ANCA positive Renal vasculitis GFR < 50ml/min and/or alveolar haemorrhage 17
18 FACTORIAL DESIGN 500 Patients: Severe ANCA Vasculitis Cyclophosphamide (Or Rituximab) 250 pts: Adjunctive Plasma Exchange 250 pts: No Plasma Exchange 125 pts: Standard-Dose Prednisolone 125 pts: Reduced Dose Prednisolone 125 pts: Standard-Dose Prednisolone 125 pts: Reduced Dose Prednisolone 18
19 Protocol Overview PLEX Standard GC Cyclophosphamide Azathioprine or rituximab Low Dose GC PLEX 2 weeks 3 6 months 1 year 2-7 years 19
20 Glucocorticoid Dosing Prednisolone mg/day 50% (IV MeP 1-3g) 20
21 THE NEW ERA: BIOTHERAPIES? 21
22 THE WGET STUDY Etanercept for maintenance treatment in AAV Objective: to maintain remission Obtainedin 72.4 % patients, 49% relapses No significant difference High rate of malignanciesin the etanercept group N Engl J Med 352(4):
23 INFLIXIMAB TO TREAT REFRACTORY AND SEVERE ANCA ASSOCIATED VASCULITIS 10 patients (7 GW, 2 RA vasculitis, 1 cryo) 10 responded, 5 CR, 5 PR 1 pt stoppedthe treatment (allergy) Bartolucci, Rheumatology (Oxford) 2002, 41(10):
24 INFLIXIMAB TO TREAT REFRACTORY AND SEVERE ANCA ASSOCIATED VASCULITIS Individual B V A S d 0 d 42 6 mo Fig 1. Individual BVAS on days 0 and 42, and at 6 months Bartolucci, Rheumatology (Oxford) 2002, 41(10):
25 INFLIXIMAB TO TREAT REFRACTORY AND SEVERE ANCA ASSOCIATED VASCULITIS Long termresponse 70% respondersrelapsed conclusion: suspensive treatment only Josselin, Ann Rheum Dis (9):
26 THE RELANCA STUDY Adressedto patients whorelapsedor didnot respondto an optimal CS + IS treatment Addon therapy(rituximab vs infliximab) Randomized De Menthon, Clin Exp Rheumatol 2011, 29: S63 26
27 Infliximab Infliximab 3 mg/kg D1 and D15 Evaluation D45 CR D45 PR D45 Failure J45 Infliximab 5 mg/kg Evaluation D73 6 infusions 14 infusions 5 mg/kg Stop De Menthon, Clin Exp Rheumatol 2011, 29: S63 27
28 Rituximab Rituximab 375 mg/m2 4 weekly infusions Evaluation at M2 CR or PR failure Maintenance M4 M8 and M12 stop De Menthon, Clin Exp Rheumatol 2011, 29: S63 28
29 Clinical response at M12 INFLIXIMAB N=11 RITUXIMAB N=10 CR 3 3 PR 2 4 PR + CR 5 7 Failure 6 3 De Menthon, Clin Exp Rheumatol 2011, 29: S63 29
30 22 patients screened 17 patients included 9 infliximab 8 rituximab 2 CR & 3 PR 3 failures 2 switched to IVIg, CYC 2 grumbling 1 death on D22 1 CR & 2 PR 2 deaths & 5 failures (4 6 months) Long term 1 persistent PR & 2 relapses 2 CR 1 (CS+Aza) & 1 rituximab 4 switched to rituximab 4 CR 30
31 ANCA + VASCULITIS Treatment of relapses of ANCA+ vasculitis with IgIV (IGANCA) Martinez, 2008, Arthritis Rheum 58(1):
32 IV IMMUNOGLOBULINS TO TREAT REFRACTORY AND SEVERE ANCA ASSOCIATED VASCULITIS RESULTS 21 patients have been included 20/21 initial responses at 9 months 13 CR, 1 PR, 7 relapses at24 months: 7 complete remissions Martinez, 2008 Arthritis Rheum 58(1):
33 IV IMMUNOGLOBULINS TO TREAT REFRACTORY AND SEVERE ANCA ASSOCIATED VASCULITIS Martinez, 2008 Arthritis Rheum 58(1):
34 RITUXIMAB 34
35 35
36 RAVE 1 to 3 pulses MPS CS+CYC oral, 3 to 6 months AZA months RTX 375 X 4 + CS + placebo CYC Placebo AZA CROSS OVER IF NEEDED Stone N Engl J Med 2010, 363(3):
37 RAVE: RESULTS Primary endpoint (BVAS=0, stop CS at 6 months) reached by: 63 of the 99 patients in the rituximab group 64% 52 of 98 in the control group 53% The treatment difference of 11% between the groups met the criterion for non inferiority (P<0.001) Stone N Engl J Med, 2010, 363(3):
38 RAVE: RESULTS Secondary endpoint (BVAS 0, < 10 mg CS, at 6 months) reached by: 70 patients treated with rituximab71% 61 patients in the control group62% Stone N Engl J Med, 2010, 363(3):
39 Adverse events: RAVE: RESULTS No significant differences between the treatment groups Events leading to discontinuation of treatment: 14 patients in the rituximab group 14% 17 in the control group 17% Stone N Engl J Med, 2010, 363(3):
40 RITUXVAS: RESULTS Severe adverse events occurred 14 of the 33 patients in the rituximab group 42% 4 of the 11 patients in the control group 36% Jones, N Engl J Med (3):
41 RITUXVAS: RESULTS Infections occurred in 12 of the 33 patients in the rituximab group 36% (total of 19 infections) 3 of the 11 patients in the control group 27% (total of 7 infections) Jones, N Engl J Med (3):
42 EDITORIAL C Jennette and R Falk, NEJM august 2010 Rituximab mightbeconsideredas an option for first-line therapy for induction of remission of ANCA-associated disease (since this editorial, rituximab has been approved in the USA (FDA) and in Europe, for induction only, in May 2013) 42
43 RITUXIMAB in the long term Results 43
44 44
45 45
46 Anti- MPO Anti- PR3 46
47 47
48 MAINTENANCE TREATMENT IN VASCULITIS 48
49 AZATHIOPRINE, METHOTREXATE FOR MAINTENANCE TREATMENT 49
50 ANCA+ VASCULITIDES CYCAZAREM Comparison of 3 to 6 mo. oral CYC + CS then azathioprine or oral CYC for 12 mo.+ 10 mg/d CS. After 12 mo all the patients were treated with azathioprine 150 patients followed for 18 mo. D Jayne for the EUVAS group. New Engl J Med July 2003, 349:
51 1.0.9 Survival to relapse Months Randomized trial of cyclophosphamide versus azathioprine as remission maintenance therapy for ANCA-associated vasculitis D Jayne for the EUVAS group. New Engl J Med July 2003, 349:
52 WEGENT Pagnoux C, et al, NEJM 2008, 359: 2790 Systemic Wegener s granulomatosis: 2 organs involved or kidney involvement or 1 organ involved + general symptoms (fever, weight loss ) IV CYC 0.6 g/m 2 (d1, d15, d30) Microscopic polyangiitis: with FFS g/m 2 /3 wk 6-12 mo INDUCTION Azathioprine 2 mg/kg/d or Methotrexate 25 mg/wk 12 mo MAINTENANCE Cotrimoxazole 1600 mg/d 2 yrs 52
53 % Surviving without relapse p = 0.36 WEGENT PagnouxC, et al, NEJM 2008 Relapse-free survival curves AZA n = 55 MTX n = Months from randomization Relapse-free survival at 18 mo: AZA 77.9% [ ]; MTX 82.4% Relapse-free [ ] survival at 24 mo: AZA 67.5% [ ]; MTX 72.6% [ ] 53
54 Mycophenolate mofetil is not superior to azathioprine to reduce relapses in ANCA-associated vasculitis Cumulative Incidence of Relapse Time (years) AZA MMF JAMA 2010,
55 MAINRITSAN 55
56 Maintenance treatment R = 500 mg of rituximab 2 wk 5 mo + 2 wk 6 mo 6 mo Endpoint 28 mo R R R R R Azathioprine 2 mg/kg/d then tapered 22 mo ANCA workshop 17 april
57 Results 57
58 Results: demographics 117 patients 66 men (56.4%) and 51 women (43.6%) 59 Azathioprine 47 1 st flares and 12 relapses 58 Rituximab 46 1 st flares and 12 relapses 58
59 Azathioprine group drop outs * 27/59 (45.7%) 17 major relapses (28.8%) 5 for severe adverse events (8.5%) 5 stopped treatment for other reasons, mainly personal (8.5%) * Several causes for the same patient 59
60 Azathioprine group dropouts Stop AZA M0 M12 M22 M28 8 relapses 2 relapses 7 relapses 60
61 Rituximab group drop outs * 6/58 (10.3%) 3 major relapses (5.2%) 3 stopped treatment for other reasons, personal for 1 * Several causes for the same patient 61
62 Rituximab group dropouts Stop RTX M8 M18 M 28 1 relapse 2 relapses 62
63 Immunoglobulins γ globulins D 0 M 28 AZA RTX
64 ANCA % DIAGNOSIS REMISSION (obtained with CYC) M 28 AZATHIOPRINE RITUXIMAB The same proportion of anti-pr3 and anti-mpo was observed at M28 64
65 CD19 on Rituximab B cell at M28 Relapses Remission CD19 = 0, in 3/3 patients ANCA anti PR3, + 2/ % achieved B cell reconstitution* 2 missing data 65
66 Severe adverse events (treatment-related or not) * Azathioprine: 44 in 25 patients (46.3%) Rituximab: 45 in 25 patients (43.8%) *Events not related to AAV are not considered in this presentation (ex: surgery for hernia, present before the disease occurred) 66
67 Infections Severe adverse events Azathioprine Rituximab Outcome Lung infections 2 1 recovery GI infections 1 2 recovery Herpes zooster 1 1 recovery Septicemia 1 death Tuberculosis, mycobacteria 1 1 recovery Pneumocystis 0 1 recovery 67
68 Severe adverse events Drug intolerance & miscellaneous Azathioprine Rituximab Outcome Hepatitis 3 0 recovery Lymphopenia 1 1 recovery Neutropenia 2 0 recovery Anemia 2 0 recovery Chills fever 0 2 recovery 68
69 Severe adverse events Cancers Azathioprine Rituximab Outcome Skin cancer (basocellular) Prostate cancer Pancreatic cancer 2 0 surgery 0 1 medical treatment 1 0 death 69
70 Severe adverse events Cardiovascular Azathioprine Rituximab Outcome Atrial fibrillation Venous thrombosis Aortic dissection 1 0 treatment 2 2 recovery 1 0 recovery Endocarditis 1 0 recovery 70
71 Severe adverse events Metabolic and others Azathioprine Rituximab Outcome Diabetes 4 5 treatment Hip osteonecrosis 1 1 surgery Cataract 4 2 surgery 71
72 Deaths during follow-up (28 months) 2/117 (1.7%) Azathioprine: 2 (3.3%) Septicemia 5 months after inclusion, at the time of relapse and treatment intensification Death 24 months after inclusion, of pancreatic cancer Rituximab: 0 (0%) 72
73 P =
74 P =
75 Conclusion Rituximab is superior to azathioprine to maintain remission in ANCA-associated vasculitides A 500-mg dose every 6 months is sufficient to maintain remission. Relapses are rare. Treatment tolerance was good, with a limited number of side effects, mainly transient. 75
76 Conclusion Gammaglobulinslevel decreased moderately during follow up and did not impact significantly the occurrence of infectious side effects ANCA disappeared in most patients treated with rituximab and in a minority of patients who received azathioprine 76
77 Comments and questions 77
78 Do we need treatment monitoring? ANCA CD19 Immunoglobulins Is rituximab effective on all clinical manifestations? What to do in the long term? Efficacy Tolerance 78
79 Ongoing study: MAINRITSAN 2 79
80 Objectives To determine whether treatment adapted to ANCA status and CD19 is as effective as a fixed administration schedule Safety in each arm Inclusions 162 within 11 months (completed) 80
81 Maintenance treatment R = 500 mg of rituximab 2 wk 5 mo + 2 wk 6 mo 6 mo Endpoint 28 mo R R R R R R R R R On demand Monitoring 81
82 Effectiveness on all clinical manifestations 82
83 RTX IN REFRACTORY GPA) RTX is more Efficient in Vasculitic than in Granulomatous Manifestations W Gross, with permission E-orbital granuloma (n=27) L-pulmonary masses (n=12) C-meningitis (n=12) L-alveolar hemorrhage (n=12) 0% 50% 100% n=75 % CR % improved % unchanged % refractory K-glomerulonephritis (n=26) P-PNP/mononenuritis (n=4) Holle et al Ann Rheum D significant reduction in BVAS and activity of all organ systems (p<0.05) higher rate of unchanged/refractory activity in granuloma compared to vasculitis e.g. in orbital granuloma vs. alveolar hemorrhage (p<0.05) 83
84 Long term follow up of MAINRITSAN 1 84
85 MAINRITSAN Long term follow up Median duration of follow-up: 43.6 months (IQR, months) Major relapses 10/55(18.2%)intheRTXarm 28/51(54.9%)intheAZAarm 85
86 MAINRITSAN Long term follow up Study period Extended FU 86
87 MAINRITSAN extension Results Relapse-free survival according to ANCA specificity 87
88 MAINRITSAN Long term follow up Relapse-free survival according to ANCA specificity 88
89 MAINRITSAN Long term follow up Relapse-free survival according to ANCA specificity 89
90 MAINRITSAN Long term follow up Relapse-free survival according to ANCA specificity 90
91 MAINRITSAN Long term follow up Relapse-free survival according to type of flare 91
92 MAINRITSAN Long term follow up Relapse-free survival according to type of flare 92
93 MAINRITSAN Long term follow up Relapse-free survival according to type of flare 93
94 MAINRITSAN extension Results Relapse-free survival according to type of flare 94
95 MAINRITSAN Long term follow up Median duration of follow-up: 42.7 months (IQR, months) Major relapses 10/55(18.2%)intheRTXarm 28/51(54.9%)intheAZAarm Deaths 0/55(0%)intheRTXarm 3/51(5.9%)intheAZAarm 95
96 MAINRITSAN Long term follow up 3 deaths : - 1 from infection - 1 from cancer - 1 from M. ischemia 96
97 MAINRITSAN extension Results 97
98 98
99 1. Cyclophosphamide and rituximab both effectively induce AAV remission but the FVSG recommends rituximab in the following situations (expert consensus): Patients who have already relapsed After IV CYC failure Recommendations Young patients with fertility concerns Patients who have already received >10 grams of CYC 99
100 Recommendations 2. Rituximab can be prescribed to AAV (MPA, GPA) patients, even in the absence of ANCA 3. Rituximab cannot yet be recommended for EGPA patients (no prospective study) or minor forms of GPA that do not require cytotoxic drugs 100
101 Recommendations 4. Rituximab cannot be prescribed only to achieve steroid-sparing 5. Age is not a limitation for rituximab use but its safety profile is not sufficient to propose rituximab as first-line therapy to induce remission in elderly patients 6. Combining rituximab and cytotoxic drugs at full dose is not recommended but combinations of several drugs warrant being evaluated at lower dose 101
102 Recommendations 7. Prophylaxis against infections is recommended Cotrimoxazole for PJP Anti-TB drugs if needed Vaccination is highly recommended (pneumonia, influenza) as soon as possible before treatment IVIgSHOULD NOT be prescribed systematically for infection prophyllaxy For hypogammaglobulinemicpatients, IVIgprescription should follow the recommendations established for secondary immune-deficiency management 102
103 Recommendations 8. The FVSG recommends prescribing rituximab as maintenance treatment, according to the results of the MAINRITSAN 1 trial 9. Rituximab reintroduction is not recommended for patients who developed severe side effects (cytopenia, pneumonia) 10.Monitoring of gammaglobulinlevels and CD19 is recommended but their impact on treatment decision warrants further study 103
104 The future 104
105 How to orientate treatments Adapt treatment to markers of activity Adapt treatment to markers of relapse Adapt treatment to comorbidities Adapt treatment to genetic markers able to: Precise diagnosis Identify patients: relapsers and non relapsers Identify patients who could experience infections or other side effects 105
106 British cohort 1184 pts and 5844 controls European replication cohort 1454 pts and 1666 controls Lyons et al, NEJM
107 Relationships between Clinical Subtype and ANCA Specificity in ANCA-Associated Vasculitis and Associations of the MHC Locus with Proteinase 3 ANCA and Myeloperoxidase ANCA. Lyons PA et al. N Engl J Med 2012;367: Lyons et al, NEJM
108 Conclusions Treatment of AAV is rapidly improving Rituximab is the competitor of cyclophosphamide for remission induction Other biotherapies have a more limited place and punctual place in the treatment of AAV, especially IgIV. The place of anti-tnf is very limited. 108
109 Conclusions To maintain remission, a treatment is needed Rituximab is taking the first place to maintain remission. However, the optimal treatment duration is not yet established Relapse occur also when rituximab is prescribed for maintenance, but with a delay which needs to be more precisely evaluated 109
110 Hôpital Cochin Paris Referral Center for Rare Systemic and Autoimmune Diseases 110
111 Rituximab in France A retrospective study on 80 patients The FVSG and the French Society of Internal Medicine cohort Charles P et al, Rheumatology 2013, 111
112 PRESCRIPTION OF RITUXIMAB IN FRANCE Before the results of prospective trials (RAVE, RITUXVAS) rituximab was mainly prescribed for relapses of AAV Rituximab is not yet approved for treatment of AAV and prescription can be prescribed only by or after opinion of referral centers 112
113 MAIN DISEASES Age at diagnosis, years, mean (SD) 48 (17) GPA, n (%) MPA, n (%) EGPA, n (%) Isolated RPGN, n (%) 70 (87) 7 (9) 1 (1) 2 (2) Charles P et al, Rheumatology 2013, in press 113
114 DEMOGRAPHICS ANCA status canca panca PR3 MPO ANCA-negative N (%) 64 (80) 13 (16) 65 (81) 11 (14) 3 (4) Charles P et al, Rheumatology 2013, in press 114
115 DEMOGRAPHICS Organ involvement ENT and upper airway Eye Kidney Lung and lower airway N (%) 60 (75) 32 (40) 44 (55) 57 (71) Charles P et al, Rheumatology 2013, in press 115
116 Patients characteristics at the time of the 1 st infusion Charles P et al, Rheumatology 2013, in press 116
117 Characteristics at the time of the 1 st infusion Age at 1 st rituximab cycle (years) 53 (17) Disease duration before 1 st rituximab cycle (months) 54 (19 91) Number of relapses before 1 st rituximab cycle 1 (1 2) Charles P et al, Rheumatology 2013, in press 117
118 Justification for rituximab treatment Induction of remission Frequent relapses Persistent disease activity despite therapy Fertility concern High cumulative CYC dose Malignancy Maintenance treatment N (%) 73 (91) 19 (24) 44 (55) 3 (4) 33 (41) 3 (4) 7 (9) Charles P et al, Rheumatology 2013, in press 118
119 Immunosuppressants before the 1 st RTX infusion Immunosuppressant Cyclophosphamide Azathioprine Methotrexate Mycophenolate mofetil N (%), grams 78 (97), (69), (30), 7 19 (24), 1 Charles P et al, Rheumatology 2013, in press 119
120 Other biotherapies before the 1 st infusion Biotherapy Infliximab Other biotherapies Intravenous immunoglobulins Plasma exchange N (%), months 7 (9), (24), 6 (3 9) 10 (7PE) Charles P et al, Rheumatology 2013, in press 120
121 Rituximab infusion schedule Charles P et al, Rheumatology 2013, in press 121
122 Rituximab infusion schedule 4 infusions of 375 mg/m 2 /week 2 1-g infusions at 2-week interval 4 infusions of 500 mg/week 55 (69) 17 (21) 1 (1) Charles P et al, Rheumatology 2013, in press 122
123 Combined treatments Concomitant immunosuppressive therapy CYC Azathioprine Mycophenolate mofetil Methotrexate N (%) 25 (31) 4 (5) 7 (9) 6 (8) 3 (4) Charles P et al, Rheumatology 2013, in press 123
124 Response to rituximab Charles P et al, Rheumatology 2013, in press 124
125 Before rituximab therapy N=80 6 months after 1 st rituximab infusion N=77 12 months after 1 st rituximab infusion N=77 Active disease, n (%) 73 (91) 7 (9) 14 (18) Complete remission, n (%) Partial remission, n (%) 7 (9) 51 (66) 55 (71) 0 19 (25) 11 (14) DEI median (IQR) 2 (2 4) 0 (0 0) 0 BVAS 7 (5 12) 0 (0 1) 0 VDI median 0 (0 1) 1 (0 1) 0 (0 1) Prednisone, mg 20 (9.5 44) 10 (5 12) 5 (5 10) Charles P et al, Rheumatology 2013, in press 125
126 Adverse events Charles P et al, Rheumatology 2013, in press 126
127 Infections Pulmonary infections Pseudomonas aeruginosa Aspergillus Pneumonia (no microbiologic data) Pseudomonas + Aspergillus Pseudomonas + Aspergillus + Pneumocystis + M. avium ( death) Septic shock (E. coli) Pyelonephritis Erysipelas Pneumococcal meningitis ( death) Febrile neutropenia N Charles P et al, Rheumatology 2013, in press 127
128 Charles P et al, Rheumatology 2013, in press 128
TREATMENT OF ANCA-ASSOCIATED VASCULITIS
TREATMENT OF ANCA-ASSOCIATED VASCULITIS Loïc Guillevin Hôpital Cochin, Université Paris Descartes Cours DU, 11 mars 2016 1 Disclosure of interest regarding this presentation Roche has provided, in part,
ANCA+ VASCULITIDES CYCAZAREM,
ANCA+ VASCULITIDES CYCAZAREM, q Comparison of 3 to 6 mo. oral CYC + CS then azathioprine or oral CYC for 12 mo.+ 10 mg/d CS. After 12 mo all the patients were treated with azathioprine q 150 patients followed
Recent advances in management of Pulmonary Vasculitis. Dr Nita MB
Recent advances in management of Pulmonary Vasculitis Dr Nita MB 23-01-2015 Overview of the seminar Recent classification of Vasculitis What is new in present classification? Trials on remission induction
ANCA-associated vasculitis. Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic
ANCA-associated vasculitis Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic Disclosure of Interests Abbvie, Amgen, Baxter, Bayer, Boehringer-Ingelheim, Calliditas,
Rituximab treatment for ANCA-associated vasculitis in childhood
Rituximab treatment for ANCA-associated vasculitis in childhood DISCLOSURE I have no relevant financial relationships to disclose Katharine Moore MD Nov 14, 2012 University of Colorado School of Medicine
Plasma exchanges in ANCA-associated vasculitis
Plasma exchanges in ANCA-associated vasculitis Xavier Puéchal, MD, PhD Centre de Référence des Maladies auto-immunes systémiques rares d Ile de France Hôpital Cochin Université Paris Descartes http://www.vascularites.org
Annual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Update on Granulomatosis with Polyangiitis (Wegener s) Learning Objectives Identify the clinical features of granulomatosis with
Tell me more about vasculitis. Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital
Tell me more about vasculitis Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital Talk overview Case study ANCA-associated vasculitis What is ANCA vasculitis? What causes ANCA
Vascularites associées aux ANCA Traitement par le RITUXIMAB
Vascularites associées aux ANCA Traitement par le RITUXIMAB Philippe Vanhille Néphrologie Médecine Interne Hôpital de Valenciennes Aix- en- Provence 2013 Cyclophosphamide therapy of severe systemic necrotizing
Vascularites rénales associées aux ANCA
Vascularites rénales associées aux ANCA Société Médicale des Hôpitaux de Paris 16 Mars 2012 Philippe Vanhille Néphrologie et Médecine Interne Hôpital de Valenciennes Classification of systemic vasculitis:
SMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018
SMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018 OUTLINE Renal involvement in vasculitis Curr Rheumatol Rep 2013 Renal involvement in ANCA vasculitis GN***:
Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis
New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations
The European and French networks. Christian Pagnoux, MD, MSc, MPH Mount Sinai Hospital, Toronto, Canada Cochin Hospital, Paris, France
The European and French networks Christian Pagnoux, MD, MSc, MPH Mount Sinai Hospital, Toronto, Canada Cochin Hospital, Paris, France French Vasculitis Study Group December 1980: L. Guillevin no research,
New Developments in ANCA-associated Vasculitis
New Developments in ANCA-associated Vasculitis Second International Renal Conference Bruges, March 2018 Ulrich Specks, M.D. Connor Group Foundation Professor of Medicine Mayo Clinic College of Medicine
RATIONALE. K Without therapy, ANCA vasculitis with GN is associated. K There is high-quality evidence for treatment with
http://www.kidney-international.org chapter 13 & 2012 KDIGO Chapter 13: Pauci-immune focal and segmental necrotizing glomerulonephritis Kidney International Supplements (2012) 2, 233 239; doi:10.1038/kisup.2012.26
Clinical Commissioning Policy: Rituximab For ANCA Vasculitis. December Reference : NHSCB/ A3C/1a
Clinical Commissioning Policy: Rituximab For ANCA Vasculitis December 2012 Reference : NHSCB/ A3C/1a NHS Commissioning Board Clinical Commissioning Policy: Rituximab For The Treatment Of Anti-Neutrophil
EudraCT number: Page 8 of 42
EudraCT number: 2012-001102-14 Page 8 of 42 5 Trial Synopsis Title Sponsor name North American Sponsor Disease Under Investigation An international, open label, randomised, controlled trial comparing rituximab
anti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide, corticosteroid
Online publication June 24, 2009 ANCA JMAAV 1 2 ANCA JMAAV MPO-ANCA 18 17 50 J Jpn Coll Angiol, 2009, 49: 53 61 anti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide,
Managing Acute Medical Problems, Birmingham Vasculitis. David Jayne. University of Cambridge
Managing Acute Medical Problems, Birmingham 2016 Vasculitis David Jayne University of Cambridge Disclosures Astra Zeneca, Aurinia, BIOGEN, Boehringer, Chemocentryx, Genzyme/Sanofi, GSK, Lilly, Medimmune,
New Evidence reports on presentations given at EULAR Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis
New Evidence reports on presentations given at EULAR 2011 Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis Report on EULAR 2011 presentations Anti-TNF failure and response to rituximab
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Jones RB, Cohen Tervaert JW, Hauser T, et al. Rituximab versus
EULAR/ERA-EDTA recommendations for the management of ANCAassociated
EULAR/ERA-EDTA recommendations for the management of ANCAassociated vasculitis Dr. Meharunnisha Syed III year DNB Resident (General Medicine) Narayana Health-MSH Fifteen recommendations were developed,
Evidence-based therapy for the ANCAassociated vasculitides: what do the trials. show so far? Clinical Trial Outcomes
associo far? Evidence-based therapy for the ANCAassociated vasculitides: what do the trials show so far? Anti-neutrophil cytoplasm antibody-associated vasculitides are rare multisystem inflammatory diseases
TITLE: Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical and Cost-effectiveness
TITLE: Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical and Cost-effectiveness DATE: 28 January 2015 CONTEXT AND POLICY ISSUES Granulomatosis with polyangiitis
EudraCT number: Page 9 of 46
EudraCT number: 2012-001102-14 Page 9 of 46 5 Trial Synopsis Title Sponsor name North American Sponsor Japan Sponsor Ireland Sponsor Disease Under Investigation An international, open label, randomised,
Protocol Version 2.0 Synopsis
Protocol Version 2.0 Synopsis Title Short Title Plasma exchange and glucocorticoid dosing in anti-neutrophil cytoplasm antibody associated vasculitis: a randomized controlled trial. PEXIVAS PEXIVAS Clinical
EUVAS update June 5 th Marinka Twilt
EUVAS update June 5 th 2012 Marinka Twilt Chapel Hill 2012 Classification Large Vessel Vasculitis (LVV) Medium Vessel Vasculitis (MVV) Small Vessel Vasculitis (SVV) Variable Vessel Vasculitis (VVV) Single
Wegener s Granulomatosis JUN-KI PARK
Wegener s Granulomatosis JUN-KI PARK Definition History Epidemiology Clinical symptoms Pathophysiology Treatment Wegener granulomatosis (WG) is a complex, immunemediated disorder, which along with microscopic
Review Article. Current concepts in Anti-Neutrophil Cytoplasmic Antibody (ANCA) associated Vasculitis. Milind Aurangabadkar
Review Article Vidarbha Journal of Internal Medicine Volume 23 July 207 Current concepts in Anti-Neutrophil Cytoplasmic Antibody (ANCA) associated Vasculitis Milind Aurangabadkar ABSTRACT Anti-neutrophil
Small Vessel Vasculitis
Banff- Rocky Mountain Barry Kassen, MD, FRCPC,FACP Head, Division of Internal Medicine UBC/VGH/SPH Acting Head, Division of Community Internal Medicine November, 2009 Objectives 1. To understand small
Rate of infections in severe necrotising vasculitis patients treated with cyclophosphamide induction therapy: a meta-analysis
Rate of infections in severe necrotising vasculitis patients treated with cyclophosphamide induction therapy: a meta-analysis M. Jung 1, L. Barra 2 1 Division of Rheumatology, Department of Medicine, University
Jones slide di 23
1 di 23 The patient with ANCA- associated vasculitis and pulmonary haemorrhage Rachel B Jones, Cambridge, UK Chairs:Hans-Joachim Anders, Munich, Germany Vladimir Tesar, Prague, Czech Republic Prof. Rachel
Systemerkrankungen mit Nierenbeteiligung
Systemerkrankungen mit Nierenbeteiligung ÖGN Fuschl 2012 Irmgard Neumann Wilhelminenspital Wien Induktions-Therapie Generalisiert CYC i.v. pulse = CYC oral CYCLOPS, de Groot, Ann Int Med 2009 RIT vs CYC
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
Rituximab for treatment of severe renal disease in ANCA associated vasculitis Geetha, Duvuru; Hruskova, Zdenka; Segelmark, Marten; Hogan, Jonathan; Morgan, Matthew; Cavero, Teresa; Eriksson, Per; Seo,
A COST EFFECTIVENESS ANALYSIS OF WEEKLY COMPLETE BLOOD COUNT MONITORING FOR LEUKOPENIA IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS (GPA) ON
A COST EFFECTIVENESS ANALYSIS OF WEEKLY COMPLETE BLOOD COUNT MONITORING FOR LEUKOPENIA IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS (GPA) ON CYCLOPHOSPHAMIDE By ATUL ASHOK KHASNIS, MD Submitted in
Year In Review: VasculitisPers. Disclosures. Learning Objectives. none 4/16/2018. Describe new medications for the treatment of vasculitis
Year In Review: VasculitisPers Cailin Sibley, M.D., M.H.S. Director, Vasculitis Clinic April 27 th, 2018 NTEREST DISCLOSURE Disclosures none Learning Objectives Describe new medications for the treatment
ANCA associated vasculitis in China
ANCA associated vasculitis in China Min Chen Renal Division, Peking University First Hospital, Beijing 100034, P. R. China 1 General introduction of AAV in China Disease spectrum and ANCA type Clinical
Nierenbeteiligung bei Systemerkrankungen
Nierenbeteiligung bei Systemerkrankungen ÖGN 2018 Irmgard Neumann www.vasculi*s.at Avacopan (CCX168) Small molecule, orally administered Highly selecgve C5aR inhibitor Prevented MPO- ANCA mediated GlomerulonephriGs
Small Vessel Vasculitis
Small Vessel Vasculitis Paul A Brogan Professor of Vasculitis and Consultant Paediatric Rheumatologist Department of Rheumatology Institute of Child Health and Great Ormond St Hospital, London UK P.brogan@ucl.ac.uk
Optimizing the Therapeutic Strategies in ANCA-Associated Vasculitis Single Centre Experience with International Randomized Trials
Prague Medical Report / Vol. 107 (2006) No. 2, p. 199 212 199) Optimizing the Therapeutic Strategies in ANCA-Associated Vasculitis Single Centre Experience with International Randomized Trials Vaňková
EULAR Recommendations for Conducting Clinical Studies and/or Clinical Trials in Systemic Vasculitis: Focus on ANCA-associated vasculitis
EULAR recommendations for clinical trials in vasculitis 1 EULAR Recommendations for Conducting Clinical Studies and/or Clinical Trials in Systemic Vasculitis: Focus on ANCA-associated vasculitis Bernhard
Clinical research in adult vasculitis. Calgary October 8 th, 2015
Clinical research in adult vasculitis Calgary October 8 th, 2015 Disclosures Consulting and speaker fees Hoffmann-La Roche BMS Advisory boards Hoffmann-La Roche GSK Educational subventions (CanVasc) Hoffmann-La
T he primary systemic vasculitides (PSV) are clinically
605 EXTENDED REPORT EULAR recommendations for conducting clinical studies and/ or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis Bernhard Hellmich,
Combined Infliximab and Rituximab in Necrotising Scleritis
This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the article
Lupus Nephritis New (?) Treatments. Aurélie HUMMEL Service de Néphrologie Hôpital Necker Enfants-Malades Paris
Lupus Nephritis New (?) Treatments Aurélie HUMMEL Service de Néphrologie Hôpital Necker Enfants-Malades Paris Introduction Lupus nephritis : 30-50% of patients with lupus = mortality risk factor Mok Series
Case Rep Nephrol Urol 2013;3: DOI: / Published online: January 27, 2013
Published online: January 27, 2013 1664 5510/13/0031 0016$38.00/0 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license),
End-stage renal disease in ANCA-associated vasculitis
Nephrol Dial Transplant (2017) 32: 248 253 doi: 10.1093/ndt/gfw046 Advance Access publication 6 April 2016 End-stage renal disease in ANCA-associated vasculitis Sergey Moiseev 1, Pavel Novikov 1, David
Vasculitis Updates. Christian Pagnoux, MD MSc MPH 19 November 2015
Vasculitis Updates Christian Pagnoux, MD MSc MPH 19 November 2015 Disclosures Consulting and speaker fees Hoffmann-La Roche BMS Advisory and study boards Hoffmann-La Roche GSK Sanofi Educational subventions
Long-term outcome of patients with ANCAassociated vasculitis treated with plasma exchange: a retrospective, single-centre study
Frausová et al. Arthritis Research & Therapy (2016) 18:168 DOI 10.1186/s13075-016-1055-5 RESEARCH ARTICLE Open Access Long-term outcome of patients with ANCAassociated vasculitis treated with plasma exchange:
ENFERMEDADES AUTOINMUNES SISTÉMICAS. Dr. José María Pego Reigosa
ENFERMEDADES AUTOINMUNES SISTÉMICAS Dr. José María Pego Reigosa ABSTRACT NUMBER: 2754 Comparison of Individually Tailored vs Systematic Rituximab Regimens to Maintain ANCA-Associated Vasculitis Remissions:
Update and Review on Vasculitis. Ramona Raya, MD ACP Internal Medicine Congress August 7, 2015
Update and Review on Vasculitis Ramona Raya, MD ACP Internal Medicine Congress August 7, 2015 Outline Classification and nomenclature updates Small vessel vasculitis Pathophysiology Diagnosis Management/therapeutic
CHECK LIST FORM-SCREENING
CHECK LIST FORM-SCREENING Participant Initials: Date of Birth: Evaluation Date: Were the following forms completed for this visit? Eligibility Form Done t Done Baseline medical History Form Done t Done
CHECK LIST FORM-MONTH 27 (Please note Month 27 is from enrolment not randomisation)
CHECK LIST FORM-MONTH 27 (Please note Month 27 is from enrolment not randomisation) Participant Initials: Date of Birth: Were the following forms completed for this visit? Follow Up Form Done t Done BVASWG
Understanding Myositis Medications
Understanding Myositis Medications 2015 TMA Annual Patient Conference Orlando, Florida Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Disclosures Mallinckrodt: Research Grant Genentech:
Additional file 2: Details of cohort studies and randomised trials
Reference Randomised trials Ye et al. 2001 Abstract 274 R=1 WD=0 Design, numbers, treatments, duration Randomised open comparison of: (45 patients) 1.5 g for 3, 1 g for 3, then 0.5 to 0.75 g IV cyclophosphamide
Technology appraisal guidance Published: 26 March 2014 nice.org.uk/guidance/ta308
Rituximab in combination with glucocorticoids for treating antineutrophil cytoplasmic antibody- associated vasculitis Technology appraisal guidance Published: 26 March 2014 nice.org.uk/guidance/ta308 NICE
Management of Acute Vasculitis. CMT teaching 3 rd June 2015 Caroline Wroe
Management of Acute Vasculitis CMT teaching 3 rd June 2015 Caroline Wroe Vasculitis pub quiz Match the date with the event Dr Peter McBride, Scottish Otolaryngologist describes a disease of rapid destruction
Rheumatology Advance Access published March 7, Induction treatment of ANCA-associated vasculitis with a single dose of rituximab
Original article Rheumatology Advance Access published March 7, 2014 RHEUMATOLOGY 262 doi:10.1093/rheumatology/ket489 Induction treatment of ANCA-associated vasculitis with a single dose of rituximab Tabitha
Pharmacy Management Drug Policy
SUBJECT: : Nucala (mepolizumab), Cinqair (reslizumab), & Fasenra (benralizumab) POLICY NUMBER: Pharmacy-62 EFFECTIVE DATE: 12/15 LAST REVIEW DATE: 3/5/2018 If the member s subscriber contract excludes
December 6, 2010 Asthma and Rheumatic Disorders and Vasculitis
December 6, 2010 Asthma and Rheumatic Disorders and Vasculitis Lanny J. Rosenwasser, M.D. Dee Lyons/Missouri Endowed Chair in Immunology Research Professor of Pediatrics Allergy-Immunology Division Childrens
Wegener s Granulomatosis
Wegener s Granulomatosis Authors: Professor Loïc Guillevin 1,2, Doctor Alfred Mahr Creation Date: May 2002 Update: January 2004 1 CHU Hôpital Cochin, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France
Renal involvement in vasculitis
Renal involvement in vasculitis Renal involvement in vasculitis Stephen Marks Consultant Paediatric Nephrologist Great Ormond Street Hospital for Children and UCL Institute of Child Health, London, UK.
UNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS
UNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS CanVasc meeting Montreal Nov 22 2012 Patrick Liang Service de rhumatologie Centre Hospitalier Universitaire
Recent Evidence in VasculitIs ScIence and Treatment. Management of AAV in the clinical setting
Recent Evidence in VasculitIs ScIence and Treatment Management of AAV in the clinical setting LEARNING OBJECTIVES At the end of this educational program, the participants should be able to: 1. Make a diagnosis
Everyday Vasculitis (or what questions do we get asked most!) Lucy Smyth Renal Consultant
Everyday Vasculitis (or what questions do we get asked most!) Lucy Smyth Renal Consultant What is it? Why have I got it? How can we treat it? Why do I feel like I do? What do the blood tests mean? Will
Antineutrophil cytoplasm antibody associated vasculitis: recent developments
mini review http://www.kidney-international.org & 2013 International Society of Nephrology Antineutrophil cytoplasm antibody associated vasculitis: recent developments Shunsuke Furuta 1 and David R.W.
Glucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease
Article Glucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease JulieAnne G. McGregor, Susan L. Hogan, Yichun Hu, Caroline E. Jennette, Ronald J. Falk, and Patrick
Treatment of Severe Renal Disease in ANCA Positive and Negative Small Vessel Vasculitis with Rituximab
American Journal of Nephrology Original Report: Patient-Oriented, Translational Research Am J Nephrol 2015;41:296301 Received: March 12, 2015 Accepted: May 6, 2015 Published online: June 2, 2015 Treatment
IN A STUDY OF PATIENTS WITH GPA & MPA RITUXIMAB REGIMEN DEMONSTRATED CLINICALLY SIGNIFICANT REDUCTION OF MAJOR RELAPSE RATE VS AZA 1
FDA Approved for follow-up treatment 1 * IN A STUDY OF PATIENTS WITH GPA & MPA RITUXIMAB REGIMEN DEMONSTRATED CLINICALLY SIGNIFICANT REDUCTION OF MAJOR RELAPSE RATE VS AZA 1 Rituximab regimen=roche-manufactured,
Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014
Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014 The notification letter which contains details of the decision to widen the restriction criteria for rituximab and eltrombopag
Clinical Case Conference Tuesday August 25, 2015 Dana Assis, MD
Clinical Case Conference Tuesday August 25, 2015 Dana Assis, MD CC: LE swelling and pain for three weeks HPI: 71F hx HTN, DM (A1c 9.6), HFrEF (45%), asthma, OA, cryptogenic cirrhosis p/w bilateral lower
CHECK LIST FORM-SCREENING
CHECK LIST FORM-SCREENING Participant Initials: Date of Birth: Evaluation Date: Were the following forms completed for this visit? Eligibility Form Done t Done Baseline medical History Form Done t Done
The systemic vasculitides were traditionally classified. Treatment of ANCA-associated Systemic Vasculitis. H. Michael Belmont, M.D.
60 Treatment of ANCA-associated Systemic Vasculitis H. Michael Belmont, M.D. Abstract The antineutrophil cytoplasmic antibodies (ANCA)-associated small vessel vasculitides include Wegener s granulomatosis,
Paediatric anti-neutrophil cytoplasmic antibody (ANCA) -associated vasculitis: an update on renal management
Pediatr Nephrol (2018) 33:25 39 DOI 10.1007/s00467-016-3559-2 REVIEW Paediatric anti-neutrophil cytoplasmic antibody (ANCA) -associated vasculitis: an update on renal management Lucy A Plumb 1 & Louise
NEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) Investor: Karl Mahler Thomas Kudsk Larsen (973)
NEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) 467-6800 Investor: Karl Mahler 011 41 61 687 8503 Thomas Kudsk Larsen (973) 235-3655 Biogen Idec Contacts: Media: Christina Chan (781) 464-3260
Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis
Clinical Kidney Journal, 2017, vol. 10, no. 4, 470 474 doi: 10.1093/ckj/sfx014 Advance Access Publication Date: 12 April 2017 Original Article ORIGINAL ARTICLE Immunoglobulin levels and infection risk
Rituximab (MabThera) maintenance therapy for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)
NIHR Innovation Observatory Evidence Briefing: August 2017 Rituximab (MabThera) maintenance therapy for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) NIHRIO (HSRIC) ID: 12979
Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
1 2 3 4 5 6 7 8 9 1 11 12 13 14 15 16 17 18 19 21 22 23 24 25 26 27 28 29 3 31 32 33 34 35 36 37 38 39 41 42 43 44 45 46 47 48 49 5 51 Combination Therapy With Rituximab and Cyclophosphamide for Remission
Updates from the 15 th ANCA workshop
Updates from the 15 th ANCA workshop Christian Pagnoux, MD, MSc, MPH Mount Sinai Hospital, Toronto, Canada Cochin Hospital, Paris, France Nataliya Milman, MD Ottawa, Canada Simon Carette, MD, MPhil, FRCP
ENFERMEDADES AUTOINMUNES SISTÉMICAS. Dr. J. María Pego Reigosa
ENFERMEDADES AUTOINMUNES SISTÉMICAS Dr. J. María Pego Reigosa ABSTRACT NUMBER: 888 PHASE 3 TRIAL RESULTS WITH BLISIBIMOD, A SELECTIVE INHIBITOR OF B-CELL ACTIVATING FACTOR, IN SUBJECTS WITH MODERATE-TO-SEVERE
Lupus nephritis. Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic
Lupus nephritis Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic Disclosure of Interests Abbvie, Amgen, Baxter, Bayer, Boehringer-Ingelheim, Calliditas, Chemocentryx,
Long-term follow-up of patients with severe ANCAassociated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear
http://www.kidney-international.org & 2013 International Society of Nephrology Long-term of patients with severe ANCAassociated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment
PAEDIATRIC VASCULITIS
PAEDIATRIC VASCULITIS Lawrence Owino Okong o, Mmed (UoN); Mphil. (UCT). Lecturer, Department of Paediatrics and Child Health, University of Nairobi. Paediatrician/ Rheumatologist. OUTLINE Introduction
The role of biologics in treatment of ANCA-associated vasculitis
Mod Rheumatol (2012) 22:319 326 DOI 10.1007/s10165-011-0548-y REVIEW ARTICLE The role of biologics in treatment of ANCA-associated vasculitis Chethana Dharmapalaiah Richard A. Watts Received: 29 July 2011
Acute and chronic treatments
21st Annual Meeting of the Swiss Stroke Society Lausanne, 11 January 2018 Vasculitis and stroke : Acute and chronic treatments Pr Mathieu ZUBER Service de Neurologie et NeuroVasculaire Groupe Hospitalier
Childhood Primary Central Nervous System Vascultis Treatment Protocols
Childhood Primary Central Nervous System Vascultis Treatment Protocols Last updated December 2014 Non-progressive large vessel primary CNS vasculitis* Adjunctive immunosuppression f 3 months IV Methylprednisolone
Case study 1: A Bayesian clinical trial in children with polyarteritis nodosa (PAN)
Case study 1: A Bayesian clinical trial in children with polyarteritis nodosa (PAN) Catrin Tudur Smith Department of Biostatistics University of Liverpool cat1@liv.ac.uk CLINICAL TRIALS IN SMALL POPULATIONS
Maintaining remission in granulomatosis with polyangiitis (Wegener s)
Maintaining remission in granulomatosis with polyangiitis (Wegener s) Since the introduction of combined immunosuppressive therapy with oral cyclophosphamide (CYC) and glucocorticosteroids in the 1970s,
IRACON Management of Lupus Nephritis: Old is gold, New is Trendy
IRACON 2016 Management of Lupus Nephritis: Old is gold, New is Trendy First episode of LN (III/IV): Induction Low dose is equally considerable as high dose CYC Switch to the other agent if no improvement
ANCA-associated vasculitis with renal involvement: an outcome analysis
NDT Advance Access published April 6, Nephrol Dial Transplant () 1 of 9 DOI: 1.193/ndt/gfh161 Original Article ANCA-associated vasculitis with renal involvement: an outcome analysis Sven Weidner 1, Steffen
Physiopathologie des vascularites associées aux ANCA
Physiopathologie des vascularites associées aux ANCA Benjamin Terrier Centre de Référence pour les Maladies AutoImmunes Systémiques Rares Hôpital Cochin, Université Paris Descartes Paris, France Fibrinoid
FOR PUBLIC CONSULTATION ONLY. Evidence Review: Rituximab for immunoglobulin G4-related disease (IgG4-RD)
Evidence Review: Rituximab for immunoglobulin G4-related disease (IgG4-RD) NHS England FOR PUBLIC CONSULTATION ONLY Evidence Review: Rituximab for immunoglobulin G4-related disease (IgG4- RD) First published:
TRANSPARENCY COMMITTEE OPINION. 8 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,
Vasculitis. Edward Dwyer, M.D. Division of Rheumatology. Vasculitis
Edward Dwyer, M.D. Division of Rheumatology VASCULITIS is a primary inflammatory disease process of the vasculature Determinants of the Clinical Manifestations of : Target organ involved Size of vessel
Vasculitis Roundup 2017
Vasculitis Roundup 2017 Nader A. Khalidi, MD, FRCPC Associate Professor August 2, 2017 Objectives 1. Update on Small, Medium and Large Vessel Vasculitis 2. Update on Imaging in Vasculitis 3. Update on
Cyclophosphamide cerebral vasculitis dosing
Cyclophosphamide cerebral vasculitis dosing The Borg System is Cyclophosphamide cerebral vasculitis dosing Cerebral vasculitis or central nervous system vasculitis is vasculitis involving the brain and
Early plasma exchange improves outcome in PR3-ANCA-positive renal vasculitis
Early plasma exchange improves outcome in PR3-ANCA-positive renal vasculitis J.W. Gregersen 1, T. Kristensen 1, S.R.P. Krag 2, H. Birn 1, P. Ivarsen 1 1 Department of Nephrology, 2 Department of Pathology,
Positioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab
Journal of Internal Medicine 2005; 257: 540 548 Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab P. ERIKSSON From the Department of Rheumatology,